S
leep is a complex physiological and behavioral state, which is needed for homeostasis at a cellular (neurons), organ (brain), and individual level, known to be fundamental for survival. Despite its importance, it is estimated that one third of the adult population is sleep deprived 1 or complains about sleep disturbances. 2 Sleep disorders, classified into 6 major categories according to the recent International Classification of Sleep Disorders, 3 determine sleep fragmentation, which in turn induces autonomic nervous system dysfunction, increases inflammation, alters coagulation, and induces oxidative stress responses. 4, 5 Sleep deprivation (SD)/fragmentation has been linked to several pathological conditions, including stroke (in the present review, the term stroke always refers to ischemic stroke). 6, 7 In the first part of this review, we address the role of sleep modulation in the pathophysiology of brain ischemia (Figure 1 ), [8] [9] [10] [11] [12] and we briefly discuss the current epidemiological evidence linking sleep disorders to stroke risk. In the second part, we review the concept of ischemic preconditioning (IP), and we discuss the role of sleep as a potential preconditioning factor able to induce ischemic tolerance and neuroprotection. 13 
Does Sleep Play a Role in Stroke?

Animal Studies
Sleep may be artificially manipulated by inducing either SD or sleep enhancement before or after experimental stroke. Animal models have shown that increasing the length and repetition of SD after stroke is linked to detrimental effects affecting both stroke evolution and functional recovery. 9, 11, 14 Additionally, it has been shown that the number of apoptotic cells is also significantly increased in the sleep-deprived animals 9 and that neuroplasticity, axonal sprouting, and neurogenesis are significantly impaired. 15 Conversely, the pharmacological enhancement of sleep after stroke is associated with positive outcomes. Particularly, mice undergoing treatment with γ-hydroxybutyrate-a drug used to promote slow-wave sleep in humans-showed a faster recovery when compared with those treated with saline, and even a significant change of neuroplasticity-associated genes in the injured striatal region was also observed. 10 Consistent with this finding, a recent study showed that chronic injections of Baclofen-a Gamma-aminobutyric acid B receptor agonist clinically used to promote sleep-positively influences both neuroplasticity and functional outcome. 16 Neurogenesis and axonal sprouting were significantly increased after Baclofen injection 16 and slow-wave sleep during the dark phase. 16 The latter observation may be related to axonal sprouting, which is known to be associated to cortical synchronous low-frequency oscillations. 17, 18 However, it should be taken into account that γ-hydroxybutyrate 19 and Baclofen 20 are known to decrease spasticity and induce hypothermia, which may be linked to the beneficial effect observed after their injections independently from sleep modulation (for further information, please see the online-only Data Supplement, "Sleep, plasticity and stroke recovery").
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Human Studies-Stroke Risk
The strong link between sleep disorders, especially sleepdisordered breathing (SDB), and cardiovascular disease and stroke risk, is supported by several epidemiological lines of evidence. 6 Intermittent hypoxia, intrathoracic pressure changes, sympathetic activation, blood pressure swings, endothelial dysfunction, and proinflammatory state have been associated to SDB, predisposing to drug-resistant arterial hypertension, atherosclerosis, cardiac arrhythmia, and hypercoagulation. 22, 23 In the seminal observational cohort study from Yaggi et al, 24 1022 patients were enrolled; the 697 (68%) diagnosed as having obstructive sleep apnea showed an increased risk of stroke and death from any cause independently from other risk factors, including hypertension. This risk association has been confirmed by a meta-analysis of prospective clinical and population-based studies suggesting that SDB is an independent stroke predictor (odds ratio, 2.24; confidence interval, 1.57-3.19), especially in man. 25 Furthermore, a recent review evaluated the effect of SDB on stroke outcome in 1203 patients, showing a dose-response relationship between the severity of SDB and risk of recurrent events and all-cause mortality in stroke and patients with transient ischemic attacks (TIAs). 26 Continuous positive airways pressure-the gold standard to treat obstructive sleep apnea-is known be effective in reducing sleep fragmentation and arterial hypertension. 27 Several randomized studies investigated the effect of continuous positive airways pressure in reducing cardiovascular and stroke risk leading to controversial results according to a recent meta-analysis. 28 In particular, the recent SAVE study (Sleep Apnea Cardiovascular Endpoints) investigating 2717 patients with cardiovascular diseases (1183 with stroke) and obstructive sleep apnea concluded that continuous positive airways pressure intervention does not prevent the risk of further Figure 1 . The vicious and virtuous circles of sleep and stroke interaction. Sleep disruption after experimental stroke is detrimental, whereas promoting sleep after an ischemic event facilitates neuroplasticity and recovery in turn determining a better stroke outcome. REM indicates rapid eye movement; and SWS, slow-wave sleep.
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December 2017 cardiovascular events in patients with moderate-to-severe obstructive sleep apnea. 29 It should be noted, however, that a suboptimal nightly use of continuous positive airways pressure (3.3 hours in the latter study) might be insufficient to provide an efficacious cardiovascular protection effect.
The risk of stroke related to other sleep disorders, such as insomnia or restless leg syndrome, should be cautiously considered (for further information, please see the online-only Data Supplement, "Stroke and cardiovascular risk: the role of sleep duration and shift work"). 6, 30, 31 Preconditioning and Stroke
Animal Studies
Cerebral ischemia activates a cascade of detrimental events but also triggers a coordinated response that attempts to counteract tissue damage. Several mechanisms of self-protection have been proposed going from autophagy and metabolism reduction at an early stage to epigenetic events at a later stage, including DNA methylation, histone modification, and microRNAs (small RNA molecules that can control their target gene expression post-transcriptionally). 32, 33 The phenomenon of ischemic tolerance or preconditioning, defined as the application of a potentially harmful stimulus, near to but below the threshold of cell damage, which promotes the tolerance of the brain to subsequent ischemic injury, efficaciously demonstrates the potential for self-protection of the brain and allows dissecting the underling biological mechanisms. 34 Several stimuli may be used to induce tolerance, such as hypoxia (IP), inflammatory mediators, metabolic blockers, anesthetics, cortical spreading depolarization (CSD), seizures, 34 and SD. 8, 13 Most of the preconditioning treatments, including SD, 13 reprogram the gene response to ischemia inducing a downregulated gene expression, particularly related to inflammation, metabolism, cell cycle regulation, and ionchannel activity. 13, 34 Genes involved in energy metabolism and protein turnover are also downregulated, pointing either to the reduction of energy expenditure or the improvement of the efficiency of energy metabolism. 35 A concomitant upregulation of genes related to cell cycle checkpoints is induced, leading to a reversible cell cycle arrest to allow time for damage repair. Conversely, mitosis and other processes such as the G1/S transition, differentiation, proliferation, and cell death are downregulated. 13 In addition, IP induces the expression of genes involved not only in neuroprotection but also in restorative mechanisms, such as neurogenesis 36, 37 and angiogenesis. 38 IP may also antagonize one of the major pathogenic mechanisms of the ischemic cascade, that is, excitoxicity/CSD, characterized by an excessive synaptic release of glutamate. IP may induce tolerance either by lowering excessive glutamate release or by increasing glutamate uptake. 34 Furthermore, IP may inhibit excitatory pathways through the downregulation of NMDA (N-methyl-d-aspartate) and AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate) receptors, which result abnormally activated from ischemic events. 39 It has been hypothesized that IP may underlie neuroprotection through 3 phases of molecular alterations. 40 The priming phase occurs within the first few hours of preconditioning, inducing an increase of inflammatory serum cytokines and others genes that may finally mediate neuroprotection. After the priming phase, the system becomes refractive to subsequent injury for an extended period of time, from 1 to 7 days. Potential mediators of this phase are microRNA, epigenetic factors, and autophagy-related changes in metabolism. 40 Finally, the third phase is the neuroprotective phase given by the reprogrammed response to the injury results. 40 Several studies indicate that preconditioning suppresses damaging genes during ischemic injury and induces the expression of unique genes that are not normally expressed in ischemic animals alone. 13 Preconditioning may help to identify mechanisms for brain protection and regeneration, providing opportunity for clinical translation. One potential approach is to therapeutically exploit some of the mediators identified by IP. Currently, some of these mediators are being tested in clinical trials. For instance, erythropoietin, 41 nitric oxide, 42 and interleukin 1 receptor antagonist 43 and finally, hypothermia 44 have been already tested in humans to reduce ischemic injuries. Another clinical approach of IP in humans is the use of remote ischemic conditioning (RIC), classically consisting of short ischemic intervals to a limb/arm to protect target organs, such as heart and brain. RIC is by far one of the most studied approaches, likely because of its clinical applicability, its low-cost noninvasive nature.
Human Studies
Despite the encouraging experimental evidence, the bench-tobedside transition is limited by several factors. The most important is that in the clinical context, such as acute myocardial infarction or stroke, the unpredictable occurrence of the pathological event does not allow us to pretreat patients with a preconditioning agent/strategy nor to administer a preconditioning mimetic agent just before the infarction. However, preconditioning may be used to reduce the ischemic risk during planned cardiovascular procedures or in conditions where a delay in neurological deficits can be predicted or when the damage may be anticipated. For instance, 2 phase 1 trials showed the safety of RIC in aneurysmal subarachnoid hemorrhage (a condition characterized by a long clinical instability with a high rate of delayed ischemic neurological deficit), with no increase in the risk of deep venous thrombosis or in delayed ischemic neurological after RIC. 45, 46 A more recent prospective trial proved a better functional outcome in patients treated with RIC. Given the unpredictable nature of stroke, IP is not applicable, but other strategies have been proposed to overcome this limitation. RIC is, indeed, known to provide protection not only when administered before ischemia, but also when applied during ischemia (remote ischemic perconditioning [RIPerC] ). 48 In a phase 3 clinical trial, RIPerC during transportation to hospital had no effect on penumbral salvage, infarct size, or infarct progression as measured by magnetic resonance imaging and 3-month clinical outcome; however, when adjusted for baseline severity of hypoperfusion, a voxelby-voxel analysis demonstrated increased tissue survival after 1 month suggesting that prehospital RIPerC may be neuroprotective. 49 A French multicenter randomized trial is ongoing to evaluate RIPerC early after stroke. 50 Taken together, these data suggest the clinical applicability of RIPerC; however, the efficacy and safety of this technique need to be confirmed in adequately powered trials, based on solid and rigorous preclinical testing, with standardized conditioning protocols.
Despite the lack of direct therapeutic implications, it is interesting to remember that several studies have aimed to test the hypothesis that an antecedent history of TIA or preinfarction angina induces ischemic tolerance with subsequent reduction in stroke/myocardial infarction severity similar to IP. For instance, 2 retrospective studies showed that the severity of subsequent stroke was reduced, and the outcome improved in patients with a previous TIA. 51, 52 A small neuroimaging study demonstrated a beneficial effect of TIAs on magnetic resonance imaging lesion size suggesting the existence of endogenous neuroprotection in the human brain, 53 and a large German prospective cohort 54 showed a lower stroke severity in patients with a preceding TIA. Another prospective study showed that preceding TIA was significantly associated with a lower probability for in-hospital case fatality after adjustment for potential confounds/pathogeneses. 55 However, conflicting results have also been reported. 56 
Sleep and Preconditioning
We have already presented the findings on the effect of pharmacological enhancement of sleep after ischemic stroke, supporting the idea that sleep is critical for recovery after cerebral ischemia. 10, 16 It has also been shown in different experimental settings that SD before ischemia is neuroprotective, improves functional performance, and reduces the signs of ischemic brain damage. 8, 12, 57, 58 In other terms, SD before ischemia acts as a form of preconditioning able to induce tolerance to ischemia. Sleep rebound 59 is one of the mechanisms through which acute SD before ischemia might induce neuroprotection 8, 12, 58 in line with the strong evidence that one of the main functions of nonrapid eye movement sleep is related to cortical plasticity. 60 Interestingly, 2 independent experimental studies proved in rodents that tolerance induced by RIC is dependent on sleep gain after treatment 61 and is effectively induced only when sleep rebound after stroke is observed 8 Preconditioning via SD induces a significant reduction in inflammatory response and apoptotic processes that strongly and negatively influence stroke outcome. 13, 57, 58 A complex gene expression reorganization has been observed after SD: the protective pattern shares several similarities with other forms of preconditioning (Figure 2) . 13 Rats treated with SD preischemia for preconditioning display a reduction in apoptosis and suppression of neuronal death. 13 Yet, inflammatory response has been observed to be downregulated in SD preischemia animals, probably caused by a preactivation of the immune system before stroke. 13 Those animals also showed an upregulation of genes related to cell cycle checkpoints, rising to a sort of cell hibernation during which neurons could better resist the consequences of ischemia. 35 As in the case of classic IP, not only attenuation of negative responses to ischemia but also increase in neurogenesis has been proposed to have a role in SD preconditioning, 14 consistent with studies where pharmacological sleep promotion after stroke promotes neurogenesis in the peri-infarct region. 16 Two genes, MCH and OX, seem to be specifically upregulated exclusively in SD preconditioning, suggesting that these 
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genes play a key role in such mechanism and may represent a future therapeutic target. 13 Another factor that may be relevant and specific for SD precondition is adenosine. Adenosine plays a role in sleep control, and in particular, the adenosine A1 receptor has been found to be increased after SD in humans 62 and animals 63 suggesting its role in SD preconditioning. 64 
Role of CSD
Spreading depolarization is a depolarization wave that propagates across the cortical mantle, basal ganglia, and other cerebral grey matter structures with a velocity between 2 to 9 mm/ min. The hallmark of CSD is the near-complete breakdown of the neuronal ion gradients with dramatic loss in the free energy of neurons, whereas cellular death is characterized by the complete loss of active ion gradients and free energy. No state of neurons is thus closer to cell death than CSD, but neurons can recover from it under otherwise favorable circumstances. 65 CSDs have been measured in patients with various brain disorders, including ischemic and hemorrhagic stroke and traumatic brain injury. 66 In experimental stroke, CSD exacerbates neuronal injury through prolonged ionic breakdown and spreading ischemia. Interestingly, the reduction of the number of CSDs by using transcranial direct current stimulation significantly reduces the infarct size during the acute phase of ischemic stroke. 67 Despite numerous evidence for a detrimental role of CSD in infarct growth, cycling of depolarizations around the lesions might, on the contrary, also initiate upregulation of the neurobiological responses involved in repair and protection. The latter represent a sort of preconditioning property, and, as such, CSD can induce a tolerance effect on later ischemic events. Mechanisms underlying CSDinduced neuroprotection involve upregulation of cytokines and growth factors, downregulation of metabolism, altered neurotransmission, NO signaling, and cellular stress responses. 68, 69 BDNF (brain-derived neurotrophic factor), which represents one of the major mediators of neuroplasticity, 70 has been described to play a prominent role in preconditioning by CSD. Indeed, BDNF-deficient mice preconditioned with CSD for 48 hours showed a reduced ischemic tolerance compared with wild-type mice that instead had a potent tolerance by showing 35% reduction of infarct volume. 71 CSD can be experimentally induced by the application of KCl to the neocortex and is known to reduce, under proper experimental settings, the occurrence of a subsequent CSD. It should be noted that at least part of the preconditioning effects attributed to CSD could also be a direct consequence of the lesion induced by the local potassium application. Indeed, it was shown that even a small cortical lesion, by itself, is sufficient in inducing tolerance to ischemia. 72 It has been suggested that CSD may exert its neuroprotective effects when KCl is applied epidurally rather than intracortically; 71 however, no systematic investigation has been conducted to date to determine whether the protective effects provided by CSD preconditioning differ depending on the induction method and timing. 69 Interesting results on the interplay between sleep and CSD might also contribute to the interpretation of the protective side of CSD. Although the effect of CSD on sleep (and vice versa) is still poorly understood and limited data are available, few studies in rats found that CSD increases nonrapid eye movement sleep, 73 and a local and transitory increase of nonrapid eye movement-slow wave activity is observed after in vivo unilateral CSD. 74 An increased expression of Arc (activity-regulated cytoskeleton-associated protein), BDNF, and NGFI-A (nerve growth factor-induced gene A) was also found in this latter experiment, suggesting that the observed slow-wave activity increase may be considered a marker of neuroplasticity. Interestingly, the same genes are involved in the neuroprotection cascade in the ischemic penumbra. 75 In other terms, CSD, facilitating sleep, might be able to promote a local enhancement of cortical plasticity via slow-wave activity. It has also been shown that, 72 hours of, SD is able to increase CSD velocity in rats 76 consistent with a facilitator effect of SD on CSD propagation.
We can argue that CSD is like a 2-sided medal, with one good side (the neuroprotection properties shown by the preconditioning experiments) and a bad one (the evidence of a harmful role of CSD in metabolically compromised tissue in experimental ischemia and in several human conditions). One possibility is that CSD acts differently in early and late/ chronic phases of stroke. Brain excitability, indeed, passes through different phases during the first weeks after stroke; acute ischemia triggers neuronal death via depolarizations and excitotoxicity, in contrast, in the chronic phase-enhanced tonic gamma-aminobutyric acid currents and synaptic glutamate signaling promote BDNF release.
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Conclusions and Future Directions
Epidemiological data converge to indicate that inadequate sleep duration or pathological sleep fragmentation (especially when secondary to SDB where other factors, such as intermittent hypoxemia, might concur) pose a substantial but still underscored 2 hazard for cerebrovascular morbidity and mortality. 6 Sleep actively interferes with the cascade of harmful events in cerebral ischemia at different levels, including inflammatory responses, neurotransmitters activity, and gene expression. 13 Preliminary data 73, 74 support the view that sleep may also influence the occurrence of CSD-a neurophysiological phenomenon known to exacerbate neuronal injury after stroke.
SD in the acute phase of experimental stroke aggravates lesion evolution and negatively impacts the functional outcome, whereas sleep enhancement after experimental stroke is associated with a faster recovery and with a facilitation of neuroplasticity ( Figure 3 ). In addition, poststroke sleep changes in humans seem to support poststroke neuronal plasticity underlying clinical recovery. 7 A strong theoretical and experimental framework supports the view that SD preconditioning positive effects are mediated by sleep rebound/increase in the early phase after stroke, so we argue that strategies aimed to enhance sleep after ischemia should be implemented. Noninvasive brain stimulation, either transcranial direct current stimulation or trancranial magnetic stimulation, has been successfully used to promote sleep (especially slow-wave activity) 79, 80 ; however, these methods might be impractical, and their safety after stroke, especially for chronic long-term exposure, is still unknown. Attention has been given to the possibility of enhancing slow waves by using more physiological stimuli, such as repeated acoustic stimulation during sleep. 81 Sleep-modulating drugs, such as baclofen or γ-hydroxybutyrate, that proved to be promising in experimental stroke models may be translated into the clinical practice if their efficacy is confirmed after appropriate clinical trials. 10, 16, 82 IP proved to be clearly effective in experimental stroke models; however, only RIC proved to be a reasonable approach to date in the bench-to bed-side transfer. RIC is, indeed, an easy and safe way to induce tolerance to ischemic insult and has already been shown to be safe in cardiological settings and in aneurysmal subarachnoid hemorrhage. Promising data point that RIC may also be applied to the early phase of stroke, and, indeed, clinical trials are ongoing. TIA, given the high risk of subsequent stroke, might be seen as the ideal clinical condition to test potential preconditioning approaches, including RIC or sleep-enhancement therapies.
To conclude, our literature review highlights the potential beneficial role of sleep promotion after an ischemic event and that good sleep (ie, optimal sleep duration and treatment of potential sleep disorders) is essential to prevent ischemic stroke and facilitate functional recovery after brain ischemia, given the prominent role of sleep in brain plasticity.
